Invesco Ltd. Acquires 4,942 Shares of Amedisys, Inc. (NASDAQ:AMED)

Invesco Ltd. raised its stake in shares of Amedisys, Inc. (NASDAQ:AMED - Free Report) by 5.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 90,847 shares of the health services provider's stock after purchasing an additional 4,942 shares during the period. Invesco Ltd. owned 0.28% of Amedisys worth $8,248,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Norges Bank bought a new stake in Amedisys during the fourth quarter worth about $83,061,000. Wealthfront Advisers LLC bought a new position in shares of Amedisys during the fourth quarter worth $72,970,000. Pacer Advisors Inc. boosted its position in shares of Amedisys by 11,621.9% during the fourth quarter. Pacer Advisors Inc. now owns 558,197 shares of the health services provider's stock worth $50,679,000 after purchasing an additional 553,435 shares in the last quarter. Birnam Oak Advisors LP bought a new position in shares of Amedisys during the fourth quarter worth $15,832,000. Finally, Calamos Advisors LLC raised its stake in shares of Amedisys by 22.7% in the 4th quarter. Calamos Advisors LLC now owns 487,444 shares of the health services provider's stock valued at $44,255,000 after purchasing an additional 90,097 shares during the period. Institutional investors and hedge funds own 94.36% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the company. Royal Bank of Canada reaffirmed an "outperform" rating and set a $100.00 price objective on shares of Amedisys in a research report on Wednesday, April 16th. Stephens reiterated an "equal weight" rating and set a $101.00 target price on shares of Amedisys in a report on Tuesday, March 4th. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $100.75.

Amedisys Price Performance

NASDAQ:AMED traded up $0.17 during trading hours on Tuesday, reaching $94.86. 111,020 shares of the company were exchanged, compared to its average volume of 405,030. The company has a market capitalization of $3.11 billion, a P/E ratio of 37.64, a P/E/G ratio of 1.78 and a beta of 0.89. Amedisys, Inc. has a 1-year low of $82.15 and a 1-year high of $98.95. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.19 and a quick ratio of 1.19. The business has a 50 day moving average of $92.25 and a 200 day moving average of $91.74.

Amedisys (NASDAQ:AMED - Get Free Report) last issued its earnings results on Wednesday, April 23rd. The health services provider reported $1.25 earnings per share for the quarter, beating analysts' consensus estimates of $1.13 by $0.12. The firm had revenue of $594.78 million for the quarter, compared to the consensus estimate of $597.43 million. Amedisys had a return on equity of 12.20% and a net margin of 3.57%. The company's revenue was up 4.1% compared to the same quarter last year. During the same quarter last year, the business posted $1.03 EPS. Research analysts forecast that Amedisys, Inc. will post 4.4 EPS for the current year.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.